SI1546088T1 - Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva - Google Patents

Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva

Info

Publication number
SI1546088T1
SI1546088T1 SI200332415T SI200332415T SI1546088T1 SI 1546088 T1 SI1546088 T1 SI 1546088T1 SI 200332415 T SI200332415 T SI 200332415T SI 200332415 T SI200332415 T SI 200332415T SI 1546088 T1 SI1546088 T1 SI 1546088T1
Authority
SI
Slovenia
Prior art keywords
diseases
immuno
organ
compounds
treatment
Prior art date
Application number
SI200332415T
Other languages
English (en)
Slovenian (sl)
Inventor
Eliahu Kaplan
Original Assignee
Novaremed Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ltd. filed Critical Novaremed Ltd.
Publication of SI1546088T1 publication Critical patent/SI1546088T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/3332—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
  • Indole Compounds (AREA)
SI200332415T 2002-10-03 2003-10-01 Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva SI1546088T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41550802P 2002-10-03 2002-10-03
EP03758581.7A EP1546088B1 (en) 2002-10-03 2003-10-01 Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
PCT/IB2003/004993 WO2004031129A2 (en) 2002-10-03 2003-10-01 Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection

Publications (1)

Publication Number Publication Date
SI1546088T1 true SI1546088T1 (sl) 2015-04-30

Family

ID=32069867

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332415T SI1546088T1 (sl) 2002-10-03 2003-10-01 Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva

Country Status (12)

Country Link
US (2) US7642290B2 (enExample)
EP (1) EP1546088B1 (enExample)
JP (1) JP4667870B2 (enExample)
AU (2) AU2003274605A1 (enExample)
CA (1) CA2500935C (enExample)
CY (1) CY1116107T1 (enExample)
DK (1) DK1546088T3 (enExample)
ES (1) ES2535975T3 (enExample)
IL (1) IL167631A (enExample)
PT (1) PT1546088E (enExample)
SI (1) SI1546088T1 (enExample)
WO (1) WO2004031129A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1546088E (pt) 2002-10-03 2015-03-16 Novaremed Ltd Compostos para utilização no tratamento de doenças auto-imunes, de doenças imuno-alérgicas e de rejeição de órgãos ou tecidos transplantados
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
FR2892923B1 (fr) * 2005-11-08 2009-01-16 Engelhard Lyon Sa Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
ES2542344T3 (es) * 2006-05-09 2015-08-04 Novaremed Ltd. Uso de inhibidores de tirosina cinasa Syk para el tratamiento de trastornos proliferativos celulares
EP2099741A2 (en) * 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
EP2003118A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2014287A1 (de) * 2007-06-13 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Verwendung von Zimtsäurederivaten als Modulatoren des EP2-Rezeptors
CA2693645A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
GB0804213D0 (en) * 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
PL2475361T3 (pl) * 2009-09-09 2020-07-13 Novaremed Ltd. N-podstawione benzenopropanoamidy do stosowania w leczeniu bólu i stanu zapalnego
GB201116335D0 (en) * 2011-09-21 2011-11-02 Novaremed Ltd A method of treating or preventing affective disorders
AU2012348529B2 (en) 2011-12-08 2017-03-30 Novaremed Ltd. Isolated stereoisomeric forms of (S) 2-N (3-O-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide
WO2015173813A1 (en) * 2014-05-14 2015-11-19 Novaremed Ltd. Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes
ES2578377B1 (es) * 2014-12-22 2017-05-04 Consejo Superior De Investigaciones Científicas (Csic) Compuestos moduladores del sensor neuronal de calcio dream y sus usos terapéuticos.
CA3036999A1 (en) 2016-09-14 2018-03-22 Invisalert Solutions, LLC Tamper resistant clasp and wristband apparatus and associated patient monitoring system and method of use
RU2020122331A (ru) 2018-01-10 2022-02-10 Брайтсид, Инк. Способ модуляции метаболизма
US12017973B2 (en) 2018-06-22 2024-06-25 Basf Se Amino acid based surfactants as formulants for biocides
USD906359S1 (en) 2018-07-05 2020-12-29 Invisalert Solutions, Inc. Display screen with graphical user interface
WO2020152226A1 (en) 2019-01-23 2020-07-30 Novaremed Ltd. Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
EP4003060A4 (en) * 2019-07-29 2023-08-02 Brightseed, Inc. METHOD OF IMPROVING DIGESTIVE HEALTH
US12094318B2 (en) 2019-09-11 2024-09-17 Invisalert Solutions, Inc. Wireless patient monitoring compliance system
US12315353B1 (en) 2024-06-04 2025-05-27 Invisalert Solutions, Inc. Patient safety monitoring method and apparatus
US12355745B1 (en) 2024-10-28 2025-07-08 Invisalert Solutions, Inc. Secure mobile device management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
JPS5236606A (en) * 1975-09-12 1977-03-22 Tanabe Seiyaku Co Ltd Process for preparation of amino compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4908322A (en) 1985-09-06 1990-03-13 The United States Of America As Represented By The Department Of Health And Human Services Derivatization of amines for electrochemical detection
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
JPH08503450A (ja) * 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド）
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5566064A (en) 1995-05-26 1996-10-15 Apple Computer, Inc. High efficiency supply for electroluminescent panels
WO1997023202A1 (en) * 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
WO1997029079A1 (en) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
ID19116A (id) 1996-10-15 1998-06-18 Nippon Catalytic Chem Ind Bahan pengabsorpsi air dan proses produksinya
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
WO2002046176A1 (en) * 2000-12-05 2002-06-13 Nippon Chemiphar Co., Ltd. Ppar (peroxisome proliferator activated receptor) activators
PT1546088E (pt) 2002-10-03 2015-03-16 Novaremed Ltd Compostos para utilização no tratamento de doenças auto-imunes, de doenças imuno-alérgicas e de rejeição de órgãos ou tecidos transplantados
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases
RU2309144C2 (ru) 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
ES2542344T3 (es) * 2006-05-09 2015-08-04 Novaremed Ltd. Uso de inhibidores de tirosina cinasa Syk para el tratamiento de trastornos proliferativos celulares
KR20100087099A (ko) 2007-09-17 2010-08-03 아카데미아 시니카 플렉트란투스 암보이니쿠스 추출물에 의해 염증 및 염증-관련 질병을 치료하기 위한 조성물 및 방법
CN101503373B (zh) 2009-03-13 2013-07-24 山东大学 2-氨基-1-(4-硝基苯基)-1-乙醇类金属蛋白酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
CA2500935A1 (en) 2004-04-15
US20060135620A1 (en) 2006-06-22
AU2003274605A1 (en) 2004-04-23
EP1546088B1 (en) 2014-12-17
WO2004031129A3 (en) 2004-07-15
ES2535975T3 (es) 2015-05-19
EP1546088A2 (en) 2005-06-29
US7642290B2 (en) 2010-01-05
US20100069454A1 (en) 2010-03-18
PT1546088E (pt) 2015-03-16
JP4667870B2 (ja) 2011-04-13
DK1546088T3 (en) 2015-03-30
CA2500935C (en) 2014-09-23
AU2010257331B2 (en) 2012-11-08
AU2010257331A1 (en) 2011-01-13
JP2006501298A (ja) 2006-01-12
IL167631A (en) 2012-03-29
CY1116107T1 (el) 2017-02-08
WO2004031129A2 (en) 2004-04-15
US8309606B2 (en) 2012-11-13

Similar Documents

Publication Publication Date Title
SI1546088T1 (sl) Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva
IL291162A (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
PL1641918T3 (pl) Komórki poporodowe do zastosowania w leczeniu choroby serca i układu krążenia
PL1656372T3 (pl) Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
EP1641378A4 (en) METHOD AND DEVICES FOR TREATING SKIN Lions
AU2003300323A8 (en) Vascular prosthesis and methods of use
EP1638624A4 (en) MEDICAL DEVICES AND METHOD FOR REGULATING THE TISSUE RESPONSE TO VASCULAR DEVICES
IL178142A0 (en) Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
EP1648397A4 (en) EX VIVO EXPANSION OF PROGENITOR CELLS AND STEM CELLS FOR THE TREATMENT OF ORGAN DISEASES DERIVED FROM THE ENDODERM
IL179616A0 (en) Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmethanones
EP1708757A4 (en) USE OF PLURIPOTENTIAL CELLS TAKEN FROM HUMAN CORDIAL BLOOD BLOOD FOR THE TREATMENT OF DISEASE
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
IL178094A (en) Enantiomers, their use in the treatment or prevention of viral diseases, allergic immune diseases, autoimmune diseases or graft rejection, and methods of preparation of these substances
IL176027A0 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
EP1838260A4 (en) SYSTEM AND METHOD FOR TREATMENT OF CARDIAC TISSUE
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
AU2002322301A1 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
AU2003256447A1 (en) Treatment of autoimmune skin diseases
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
GB0200929D0 (en) Tissue rejection
GB0316940D0 (en) Treatment of skin and other medical conditions
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject